Clinical Trial Update: Raltitrexed and Paclitaxel for Gastric or Gastroesophageal Junction Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating raltitrexed with paclitaxel for gastric cancer and gastroesophageal junction adenocarcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• PACLITAXEL (PACLITAXEL)
• Raltitrexed (Raltitrexed)

Snippet

Sponsor: Chinese Academy of Medical Sciences | Conditions: Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | Phase 2 | Status: COMPLETED